Hansa Biopharma AB (CHIX:HNSAS) Selling, General, & Admin. Expense: kr414.5 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:HNSAS Hansa Biopharma AB CHIX:HNSAS
43 GF Score
Price kr25.64
GF Value kr16.65
! 5 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Selling, General, & Admin. Expense?

Hansa Biopharma AB CHIX:HNSAS 43 Selling, General, & Admin. Expense is kr414.5 Mil as of Jun. 2026. GuruFocus rates CHIX:HNSAS with a GF Score™ of 43/100 and a GF Value™ of kr16.65. The stock has 5 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Hansa Biopharma AB's selling, general, & admin. expense for the three months ended in Jun. 2026 was kr118.9 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2026 was kr414.5 Mil.


Hansa Biopharma AB  (CHIX:HNSAs) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Hansa Biopharma AB Selling, General, & Admin. Expense Related Terms


Hansa Biopharma AB Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB Selling, General, & Admin. Expense Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 327.27 337.86 450.49 344.27 356.55

Hansa Biopharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.52 88.41 101.62 105.56 118.93

CHIX:HNSAS vs VRTX, REGN, RVMD: Selling, General, & Admin. Expense Comparison

For the Biotechnology subindustry, Hansa Biopharma AB's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB Selling, General, & Admin. Expense vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Selling, General, & Admin. Expense falls into.


CHIX:HNSAS
43GF Score
Hansa Biopharma AB CHIX:HNSAS
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr414.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of kr414.5 Mil mean?
Hansa Biopharma AB (CHIX:HNSAS) has a Selling, General, & Admin. Expense of kr414.5 Mil as of Jun. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Selling, General, & Admin. Expense too high?
Hansa Biopharma AB's current Selling, General, & Admin. Expense is kr414.5 Mil. Overall, Hansa Biopharma AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Selling, General, & Admin. Expense compare to VRTX and REGN?
Hansa Biopharma AB's Selling, General, & Admin. Expense of kr414.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Biotechnology company?
A good Selling, General, & Admin. Expense depends on the Biotechnology industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Selling, General, & Admin. Expense is kr414.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Hansa Biopharma AB (CHIX:HNSAS) has a current Selling, General, & Admin. Expense of kr414.5 Mil. The stock's GF Value™ is kr16.65, compared to a current price of kr25.64 — trading 54% above its estimated fair value. The current Selling, General, & Admin. Expense is kr414.5 Mil. Hansa Biopharma AB's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Hansa Biopharma AB (CHIX:HNSAS), the current Selling, General, & Admin. Expense is kr414.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (CHIX:HNSAS) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr25.64 is trading 54% above its estimated GF Value™ of kr16.65.

Key valuation signals for CHIX:HNSAS:

  • Selling, General, & Admin. Expense: kr414.5 Mil
  • GF Value™: kr16.65 vs. price of kr25.64 (54% above fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the CHIX:HNSAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
43GF Score

Get the complete analysis for CHIX:HNSAS

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr25.64
Price
kr16.65
GF Value